Assembly Biosciences
Develops antiviral and liver-disease candidates through discovery and clinical development.
$34.07
After-hours close+0.08 (+0.24%)
At close$33.99(−2.33%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 68.47%13.57M sharesInsiders 1.75%347.4K sharesOther 29.78%5.90M shares
Shares outstanding 19.82M · Float 12.47M · 62.9% free float
Institutions13F, as of Mar 31, 2026
74 holders · 13.57M shares · 16 new positions · 44 increased · 17 reduced · 11 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 4.51M | 22.73% | 0 | May 8, 2026 |
| Farallon Capital Management LLC | 1.23M | 6.19% | 0 | May 15, 2026 |
| Ra Capital Management, L.P. | 1.02M | 5.15% | 0 | May 15, 2026 |
| Commodore Capital LP | 1.00M | 5.05% | 0 | May 15, 2026 |
| Janus Henderson Group PLC | 849.3K | 4.29% | +11.4K | May 18, 2026 |
| Paradigm Biocapital Advisors LP | 665.3K | 3.36% | 0 | May 15, 2026 |
| Vanguard Capital Management LLC | 490.4K | 2.47% | +490.4Knew | May 15, 2026 |
| Parkman Healthcare Partners LLC | 411.2K | 2.08% | +161.9K | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 25.10% | 4.98M | 13D | May 27, 2026 ↗ |
| Commodore Capital LP | 9.90% | 1.62M | 13G | Aug 15, 2025 ↗ |
| RA Capital Management, L.P. | 9.50% | 1.53M | 13G | Aug 18, 2025 ↗ |
| Janus Henderson Group PLC | 8.20% | 1.34M | 13G | Dec 8, 2025 ↗ |
| Steven Boydincl. Armistice Capital, LLC | 5.58% | 354.0K | Nov 14, 2024 ↗ | |
| Paradigm BioCapital Advisors LP | 5.40% | 865.3K | 13G | May 11, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 10 percent owner | 4.98M | 25.11% | May 27, 2026 |
| Jason A. Okazaki | director, officer: CEO and President | 163.4K | 0.82% | Jun 5, 2026 |
| William E. IV Delaney | officer: Chief Scientific Officer | 60.3K | 0.30% | Jun 5, 2026 |
| Nicole S. White | officer: Chief Manufacturing Officer | 48.1K | 0.24% | Jun 5, 2026 |
| Anuj Gaggar | officer: Chief Medical Officer | 42.7K | 0.22% | Jun 5, 2026 |
| John G. McHutchison | director | 18.3K | 0.09% | Apr 15, 2025 |
| Jeanette M. Bjorkquist | officer: PFO and PAO | 14.6K | 0.07% | Jun 18, 2026 |
4 ten-percent owners hold 5.99M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 16 people have not refiled in the last 18 months (195.3K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 17, 2026 | Jeanette M. Bjorkquistofficer: PFO and PAO | Sale | 29 | $23.25 | 14,560 |
| Mar 30, 2026 | Nicole S. Whiteofficer: Chief Manufacturing Officer | Sale · 2 lots | 197 | $26.69 | 37,477 |
| Mar 30, 2026 | Jeanette M. Bjorkquistofficer: PFO and PAO | Sale · 2 lots | 328 | $26.69 | 11,089 |
| Aug 8, 2025 | Gilead Sciences, Inc.10 percent owner | Purchase · 3 lots | 4,591,840 | $10.80 | 6,801,311 |
CongressHouse and Senate disclosures
Not reported.